Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0OPFVY
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Samrotamab vedotin
|
|||||
| Synonyms |
ABBV 085; ABBV-085; ABBV085; PR-1498487-MMAE
Click to Show/Hide
|
|||||
| Organization |
AbbVie, Inc.
|
|||||
| Drug Status |
Phase 1
|
|||||
| Indication |
In total 1 Indication(s)
Solid tumors [ICD11:2A00-2A0Z|2B50-2F9Z]
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
| Antibody Name |
Samrotamab
|
Antibody Info | ||||
| Antigen Name |
Leucine-rich repeat-containing protein 15 (LRRC15)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
Vedotin
|
|||||
| Puchem SID | ||||||
| ChEBI ID | ||||||
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Discovered Using Patient-derived Xenograft Model
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Objective Response Rate (ORR) |
2.10% (non-sarcomas all doses)
10.80% (sarcomas all dose) 20.00% (osteosarcoma+UPS 3.6 mg/kg) 20.00% (osteosarcoma 3.6 mg/kg) 20.00% (UPS 3.6 mg/kg) |
|||
| Patients Enrolled |
Patients with LRRC15 positive squamous cell carcinoma of the head and neck, NSCKC, breast cancer, undifferentiated pleomorphic sarcoma or osteosarcoma.
|
||||
| Administration Dosage |
0.30 up to 6.00 mg/kg on day 1, once every 2 weeks.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT02565758 | Clinical Status | Phase 1 | ||
| Clinical Description | A multicenter, phase 1, open-label, dose-escalation study of ABBV-085, an antibody drug conjugate, in subjects with advanced solid tumors. | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT02565758 | Clinical Status | Phase 1 | ||
| Clinical Description | A multicenter, phase 1, open-label, dose-escalation study of ABBV-085, an antibody drug conjugate, in subjects with advanced solid tumors. | ||||
Discovered Using Patient-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 27.90% (Day 20) | Negative LRRC15 (LRRC15-) | ||
| Method Description |
The efficacy of ABBV-085 directed against LRRC15 was assessed in several patient-derived xenograft models of UPS,LMS,and DDLPS. For efficacy study,tumors were allowed to establish to 200±50 mm3 in size before randomization into various treatment groups with 7-9 mice per group. Isotype-control,isotype-MMAE,and ABBV-085,diluted in PBS were administered at 6 mg/kg once every 4 days intraperitoneally for a total of six injections.
Click to Show/Hide
|
||||
| In Vivo Model | Liposarcoma PDX model (PDX: LPS28) | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 34.50% (Day 22) | Negative LRRC15 (LRRC15-) | ||
| Method Description |
The efficacy of ABBV-085 directed against LRRC15 was assessed in several patient-derived xenograft models of UPS,LMS,and DDLPS. For efficacy study,tumors were allowed to establish to 200±50 mm3 in size before randomization into various treatment groups with 7-9 mice per group. Isotype-control,isotype-MMAE,and ABBV-085,diluted in PBS were administered at 6 mg/kg once every 4 days intraperitoneally for a total of six injections.
Click to Show/Hide
|
||||
| In Vivo Model | Leiomyosarcoma PDX model (PDX: LMS33) | ||||
| Experiment 3 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 38.10% (Day 43) | Negative LRRC15 (LRRC15-) | ||
| Method Description |
The efficacy of ABBV-085 directed against LRRC15 was assessed in several patient-derived xenograft models of UPS,LMS,and DDLPS. For efficacy study,tumors were allowed to establish to 200±50 mm3 in size before randomization into various treatment groups with 7-9 mice per group. Isotype-control,isotype-MMAE,and ABBV-085,diluted in PBS were administered at 6 mg/kg once every 4 days intraperitoneally for a total of six injections.
Click to Show/Hide
|
||||
| In Vivo Model | Liposarcoma PDX model (PDX: LPS28) | ||||
| Experiment 4 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 87.20% (Day 20) | High LRRC15 expression (LRRC15+++) | ||
| Method Description |
The efficacy of ABBV-085 directed against LRRC15 was assessed in several patient-derived xenograft models of UPS,LMS,and DDLPS. For efficacy study,tumors were allowed to establish to 200±50 mm3 in size before randomization into various treatment groups with 7-9 mice per group. Isotype-control,isotype-MMAE,and ABBV-085,diluted in PBS were administered at 6 mg/kg once every 4 days intraperitoneally for a total of six injections.
Click to Show/Hide
|
||||
| In Vivo Model | Liposarcoma PDX model (PDX: LPS28) | ||||
| Experiment 5 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 88.70% (Day 25) | High LRRC15 expression (LRRC15+++) | ||
| Method Description |
The efficacy of ABBV-085 directed against LRRC15 was assessed in several patient-derived xenograft models of UPS,LMS,and DDLPS. For efficacy study,tumors were allowed to establish to 200±50 mm3 in size before randomization into various treatment groups with 7-9 mice per group. Isotype-control,isotype-MMAE,and ABBV-085,diluted in PBS were administered at 6 mg/kg once every 4 days intraperitoneally for a total of six injections.
Click to Show/Hide
|
||||
| In Vivo Model | Leiomyosarcoma PDX model (PDX: LMS33) | ||||
| Experiment 6 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 95.20% (Day 21) | High LRRC15 expression (LRRC15+++) | ||
| Method Description |
The efficacy of ABBV-085 directed against LRRC15 was assessed in several patient-derived xenograft models of UPS,LMS,and DDLPS. For efficacy study,tumors were allowed to establish to 200±50 mm3 in size before randomization into various treatment groups with 7-9 mice per group. Isotype-control,isotype-MMAE,and ABBV-085,diluted in PBS were administered at 6 mg/kg once every 4 days intraperitoneally for a total of six injections.
Click to Show/Hide
|
||||
| In Vivo Model | Leiomyosarcoma and undifferentiated sarcomas PDX model, (PDX: UPS7) | ||||
| Experiment 7 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100.00% (Day 22) | High LRRC15 expression (LRRC15+++) | ||
| Method Description |
The efficacy of ABBV-085 directed against LRRC15 was assessed in several patient-derived xenograft models of UPS,LMS,and DDLPS. For efficacy study,tumors were allowed to establish to 200±50 mm3 in size before randomization into various treatment groups with 7-9 mice per group. Isotype-control,isotype-MMAE,and ABBV-085,diluted in PBS were administered at 6 mg/kg once every 4 days intraperitoneally for a total of six injections.
Click to Show/Hide
|
||||
| In Vivo Model | Leiomyosarcoma and undifferentiated sarcomas PDX model, (PDX: UPS7) | ||||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.